ABTI (Alterola Biotech) Buyback Yield %: 0.00 (As of Jul. 06, 2026)


What is Alterola Biotech Buyback Yield %?

Alterola Biotech ABTI Buyback Yield % is 0.00 as of Jul. 06, 2026.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Alterola Biotech's current buyback yield was 0.00%.

Alterola Biotech Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Alterola Biotech's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterola Biotech Buyback Yield % Chart

Alterola Biotech Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Mar22 Mar23 Mar24
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.21 -0.14 0.00

Alterola Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.10 0.88 0.00 0.00 -3.66

ABTI vs SKYI, GCAN, PNXP: Buyback Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alterola Biotech's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alterola Biotech Buyback Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alterola Biotech's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Alterola Biotech's Buyback Yield % falls into.


Alterola Biotech Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Alterola Biotech's Buyback Yield for the fiscal year that ended in Mar. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 4.4245216
=0.00%

Alterola Biotech's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0.215 + 0) / 5.8699
=-3.66%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Alterola Biotech (ABTI) has a Buyback Yield % of 0.00 as of Jul. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Alterola Biotech and its competitors.
Is Alterola Biotech's Buyback Yield % too high?
Alterola Biotech's current Buyback Yield % is 0.00.
How does Alterola Biotech's Buyback Yield % compare to SKYI and GCAN?
Alterola Biotech's Buyback Yield % of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Alterola Biotech and its competitors. Alterola Biotech's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterola Biotech stock overvalued right now?
Alterola Biotech (ABTI) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Alterola Biotech (ABTI), the current Buyback Yield % is 0.00 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterola Biotech Business Description

Address 47 Hamilton Square, Birkenhead, Merseyside, GBR, CH41 5AR
Alterola Biotech Inc is a pharmaceutical company working with cannabinoid and cannabinoid-like molecules. The company operates in three focus areas: Development of regulated pharmaceuticals (human and animal health) and regulated food products; Production of low cost of goods Active Pharmaceutical Ingredient (API) and food-grade ingredients; and Formulation, and drug delivery, providing improved bioavailability, solubility and stability.